Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Gilead Sciences, Inc.NASDAQ: GILD

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 1.24B shares fell 1.0% year over year, in line with the -0.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.0% toward the trailing-twelve-month pace of -0.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
1.24B-0.9% QoQ
Last fiscal yearDec 2025
1.26B+0.0% YoY
LTMJun 2026
1.25B-0.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.0%——
1 year+0.0%——
3-year CAGR-0.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
1.26B USD
Year-over-year change
+0.0%
4-year CAGR
-0.1%

Weighted Avg Shares (Diluted) vs competitors

How GILD compares with its peers on the latest reported figures

  • GILD's LTM Jun 2026 weighted avg shares (diluted) of 1.25B shares is the 9th highest of the 10 companies compared; the peer median is 2.04B shares.
  • Its year-over-year change of -0.5% is the 5th highest of 10, against a peer median of -0.6%.
  • Over three fiscal years its annual growth of -0.2% compares with a peer median of -0.5%.
GILD Competitors Peer median
Weighted Avg Shares (Diluted) for GILD and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.71B +0.0%-0.3%
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
JNJJohnson & JohnsonLTM Sep 20262.44B +0.8%-3.0%
SNYSanofiLTM Jun 20262.43B -2.4%-0.8%
GSKGSK plcLTM Jun 20262.04B -0.9%+0.3%
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.0%-0.1%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
GILDGilead Sciences, Inc.LTM Jun 20261.25B -0.5%-0.2%
LLYEli Lilly and CompanyLTM Jun 2026896.6M -0.6%-1.9%
Peer median (excluding GILD) 2.04B-0.6%-0.5%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.